1.40
price down icon3.45%   -0.05
pre-market  Pre-mercato:  1.40  
loading
Precedente Chiudi:
$1.45
Aprire:
$1.41
Volume 24 ore:
142.98K
Relative Volume:
0.53
Capitalizzazione di mercato:
$20.90M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.2093
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
-11.39%
1M Prestazione:
+5.26%
6M Prestazione:
-24.32%
1 anno Prestazione:
-31.03%
Intervallo 1D:
Value
$1.30
$1.43
Intervallo di 1 settimana:
Value
$1.30
$1.621
Portata 52W:
Value
$0.7707
$6.40

Longeveron Inc Stock (LGVN) Company Profile

Name
Nome
Longeveron Inc
Name
Telefono
305-302-7158
Name
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
LGVN's Discussions on Twitter

Confronta LGVN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LGVN
Longeveron Inc
1.40 20.90M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-06 Iniziato ROTH MKM Buy

Longeveron Inc Borsa (LGVN) Ultime notizie

pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register

Mar 03, 2025
pulisher
Mar 03, 2025

LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews

Mar 03, 2025
pulisher
Mar 02, 2025

Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada

Mar 02, 2025
pulisher
Mar 02, 2025

Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 02, 2025
pulisher
Feb 28, 2025

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan

Feb 28, 2025
pulisher
Feb 26, 2025

LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Feb 26, 2025
pulisher
Feb 23, 2025

Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

Longeveron® Announces World Health Organization Approval of “laro - The National Law Review

Feb 21, 2025
pulisher
Feb 21, 2025

LGVNRLongeveron Latest Stock News & Market Updates - StockTitan

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq

Feb 21, 2025
pulisher
Feb 18, 2025

Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron® Announces World Health Organization Approval of - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan

Feb 18, 2025
pulisher
Feb 14, 2025

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan

Feb 14, 2025
pulisher
Feb 05, 2025

Longeveron announces board member resignation - MSN

Feb 05, 2025
pulisher
Jan 31, 2025

Longeveron announces board member resignation By Investing.com - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 30, 2025

Longeveron Board Member Neil Hare Resigns - TipRanks

Jan 30, 2025

Longeveron Inc Azioni (LGVN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):